3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
3
Head & Neck
1
Gynecologic
1
Conditions
Squamous Cell Carcinoma of Head and Neck
5
Uterine Cervical Neoplasms
1
Recurrence
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Gastrointestinal Stromal Tumors
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Breast Diseases
1
Interventions
Fulvestrant
2
Alpelisib
2
tipifarnib
1
ribociclib
1
palbociclib
1
exemestane
1
abemaciclib
1
Tamoxifen
1
STX-478
1
SF 1126
1
Panobinostat
1
PX-866
1
Metformin
1
Letrozole
1
Imlunestrant
1
Everolimus
1
Docetaxel
1
Cetuximab
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
ribociclib
×
Head & Neck
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled